Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
| Autor: | Santos, Fabio P.S., Kantarjian, Hagop M., Jain, Nitin, Manshouri, Taghi, Thomas, Deborah A., Garcia-Manero, Guillermo, Kennedy, Debra, Estrov, Zeev, Cortes, Jorge, Verstovsek, Srdan * |
|---|---|
| Zdroj: | In Blood 11 February 2010 115(6):1131-1136 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|